Felip, E.Brunsvig, P.Helland, A.Vinolas, N.Aix, S.Carcereny, E.Domine Gomez, M.Trigo Perez, J. M.Arriola, E.Garcia Campelo, R.Spicer, J.Thompson, J.Ortega Granados, A. L.Holt, R.Smethurst, D.Lorens, J.Shoaib, M.Siddiqui, A.Schoelermann, J.Lorens, K.Schmidt, E.Chisamore, M. J.Krebs, M.2025-01-072025-01-072019-10-011556-0864https://hdl.handle.net/10668/26622enbemcentinibAXLPembrolizumabEfficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLCconference outputopen access10.1016/j.jtho.2019.08.5151556-1380http://www.jto.org/article/S1556086419311980/pdf492162201200